Kopran Limited (NSE: KOPRAN) submitted its financial results for the quarter ended June 30, 2026, to the National Stock Exchange on August 7, 2026, following a board meeting held the same day. The announcement adds to a closely watched earnings cycle for the Mumbai-based pharmaceutical manufacturer, which has maintained a disciplined and unchanged dividend payout for four consecutive fiscal years.

Dividend History: Four Years of Consistency

Kopran's board has recommended or declared a final dividend of ₹3.00 per equity share every year since FY2022, with payouts announced in May of each year. The record is as follows:

The flat dividend across four years reflects a zero growth in per-share payout, indicating the company has prioritized payout stability over progressive dividend increases. There has been no interim dividend announced in the current FY2026 cycle to date, and no FY2026 final dividend has yet been declared, as the board meeting on August 7 pertained specifically to quarterly results.

Market Data Context

Complete real-time market data for KOPRAN, including the current traded price, 52-week high and low, PE ratio, sector PE, delivery percentage, and trading volumes, was not available at the time of this report. Investors are advised to refer to the NSE portal directly for live quote data before drawing yield or valuation conclusions.

For reference, at a hypothetical current market price, the dividend yield on ₹3.00 per share can be calculated as: Dividend Yield (%) = (3.00 divided by Current Market Price) multiplied by 100. Investors should apply this formula against the prevailing traded price to assess income return relative to current valuation.

Company Background

Kopran Limited is a SEBI-listed pharmaceutical company with operations spanning bulk drug manufacturing and formulations. The company's equity shares carry the ISIN INE082A01010 and are traded on the NSE. Kopran has historically catered to both domestic and export markets, with its bulk active pharmaceutical ingredient (API) segment being a key revenue contributor.

What the Q1 FY27 Results Mean for Investors

The submission of Q1 FY27 results (April to June 2026) marks the first quarterly earnings disclosure of the current fiscal year. Investors tracking Kopran will focus on revenue trajectory, EBITDA margins, and any commentary on API pricing and export demand, all of which have been variable across the Indian pharma sector in recent quarters.

The consistent ₹3.00 per share dividend over four years, while demonstrating payout reliability, also signals that earnings growth has not yet translated into a higher shareholder return in absolute per-share terms. Investors focused on dividend growth rather than dividend stability may note this stagnation as a consideration when assessing the stock relative to pharma peers that have raised payouts progressively.

The full financial results, including revenue, net profit, and segmental disclosures for Q1 FY27, are available on the NSE corporate filings portal under Kopran Limited's announcements section.